Clinical trial Recruiting at 1 site Interventional Ages 18 to 70

Mandibular advancement to reduce sleep apnea after hypoglossal nerve stimulation

Official title: Reducing Obstructive Sleep Apnea After Hypoglossal Nerve Stimulation Through

Run by Washington University School of Medicine · NCT07132307 · Data updated 2026-11-12

This will try a mandibular advancement device (a mouthpiece worn at night) to see if it reduces moderate to severe obstructive sleep apnea in adults who cannot tolerate CPAP and whose hypoglossal nerve stimulation did not help enough.

More Obstructive Sleep Apnea trials

Quick facts

Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment30 (estimated)
SponsorWashington University School of Medicine
Academic / other
Locations1 site (St Louis, Missouri)
StatusRecruiting
StartedJuly 29, 2025
Main results expectedFebruary 1, 2027
Study endsFebruary 1, 2027
Registry record updatedMarch 19, 2026
Trial IDNCT07132307 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–70 who are CPAP-intolerant, meet the study's definition of HGNS failure, can insert and remove the MAD independently, have sufficient dentition for an oral appliance, can complete home sleep testing, and have internet access for study activities.

Probably not a fit

Patients over 70, those with insufficient healthy teeth for an oral appliance, prior intolerance to MAD therapy, chronic nasal obstruction, or other exclusionary conditions are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

ROHMA is a single-arm pilot intervention testing a mandibular advancement device (MAD) in adults with moderate to severe obstructive sleep apnea who have failed hypoglossal nerve stimulation (HGNS). Eligible participants are adults treated with HGNS at Washington University between April 4, 2019 and October 20, 2024 or previously enrolled in a specified prior protocol. The study will fit participants with a MAD, require avoidance of other OSA treatments during follow-up, and use home sleep apnea tests and safety/feasibility measures to track outcomes. The primary aims are to measure effectiveness in reducing apnea events and to document device tolerability and safety in this specific post-HGNS population.

Why it matters

Potential benefit: If successful, the mandibular device could offer a noninvasive option to reduce apnea events and improve sleep for patients who failed HGNS and cannot use CPAP.

How similar studies have gone: Mandibular advancement devices have proven effective for many people with OSA, but applying MADs specifically after failed hypoglossal nerve stimulation is a new, largely untested approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 18 years.
* Ability to read, write, speak, and understand English.
* Failure of hypoglossal nerve stimulation (HGNS) therapy, defined as intolerance to HGNS or insufficient AHI reduction based on modified Sher criteria while using HGNS.
* Ability to insert and remove the mandibular advancement device (MAD) independently.
* Ability to complete all study assessments and evaluations, including home sleep apnea tests (HSAT).
* Ability to abstain from any other treatment for obstructive sleep apnea (OSA) during the entire study duration.
* Access to an internet-connected device (phone, tablet, or laptop) with a camera.

Exclusion Criteria:

* Age over 70 years.
* Inability to use a mandibular advancement device (MAD), defined as having fewer than 9 healthy teeth per dental arch.
* Prior intolerance to MAD therapy.
* Previous participation in a trial involving the use of oral appliances.
* Chronic nasal obstruction.
* Dependence on or frequent use of medications that alter consciousness, respiration, or alertness.
* Insomnia and/or use of medications to treat insomnia.
* Sleep disorders such as narcolepsy, insomnia, restless leg syndrome, or other disorders affecting sleep, and/or use of medications to treat such disorders.
* Substance abuse.
* Unstable psychiatric disorders.
* Current use of a GLP-1 receptor agonist (e.g., Zepbound, Wegovy, Ozempic, Mounjaro) with ongoing, active weight loss at the time of enrollment, or recent dose escalation within the prior 8 weeks.

Where it's running

  • Washington University School of Medicine
    St Louis, Missouri, United States
    Recruiting

Study contacts

  • Principal investigator: Jay Piccirillo, MD — Washington University School of Medicine
  • Study coordinator: Jay F Piccirillo, MD
  • Email: piccirj@wustl.edu
  • Phone: 314-362-8641

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.